Austin, Texas, United States
NCT Number: NCT02073084
A Thorough Corrected QT Interval Trial
The purpose of this study is to determine the effects of K-877 on ECG parameters with a focus on cardiac repolarization compared with placebo in healthy adult subjects.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–45 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Subject provides written informed consent before any study specific evaluation is performed.
- Subject is a healthy adult male or female volunteer, of any race and ethnicity, between the ages of 18 and 45 years, inclusive.
- Subject has a body mass index of 18 to 30 kg/m2, inclusive.
Exclusion criteria
- Subject has clinically relevant abnormalities in the screening or check in assessments.
- Subject has a supine blood pressure after resting for at least 5 minutes that is higher than 140 mm Hg systolic or 90 mm Hg diastolic, or lower than 90 mm Hg systolic or 60 mm Hg diastolic.
- Subject has a supine Heart Rate (HR) (as measured at Screening or Check-in during collection of vital signs) after resting for at least 5 minutes that is outside the range of 40 to 90 beats per minute.
Treatment and study plan
K-877 Low Dose
DrugK-877 Low Dose
moxifloxacin
DrugPlacebo
OtherK-877 High Dose
DrugK-877 High Dose
Primary outcomes
-
QTcI (QT interval corrected) duration
Time frame: 24 hrs
Sponsors and collaborators
Lead sponsor
Kowa Research Institute, Inc.
Industry
Registry information
Important dates
- Study start
- 2014
- Primary completion
- 2014
- First posted
- Feb 27, 2014
- Registry last updated
- Apr 10, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults
NCT07655960
Dyslipidemia, Dyslipidemias
Seoul, South Korea
View Trial DetailsStudy to Evaluate the Safety and the Pharmacokinetics of "UI111" and "UIC202006" Under Fed Conditions
NCT07691268
Dyslipidemia, Dyslipidemias
Seoul, Gwanak-gu 08779, South Korea
View Trial DetailsPolyunsaturated Fatty Acids-based Bars Effect on Metabolic Syndrome Patients
NCT07627555
Cardiovascular Diseases, Dyslipidemia
Lahore, Pakistan
View Trial DetailsLipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
NCT00001154
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemia
Bethesda, Maryland, United States
View Trial Details